Albert Seymour

Albert Seymour has spent more than 20 years coupling the discipline of human genetics with pharmaceutical R&D, resulting in the delivery of multiple therapeutic programs into development. As chief scientific officer of Homology Medicines, Albert is responsible for translating the company’s dual in vivo gene therapy and gene editing platform into treatments for rare genetic disorders, including advancing the world’s first gene therapy clinical trial for phenylketonuria in just under three years.